welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
terminated

Coxib-inhibition of Duodenal Polyp Growth in FAP

key information

study id #: NCT00844727

condition: Duodenal Polyposis

status: terminated

purpose:

Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.

intervention:
Drug: Rofecoxib
Drug: placebo

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close